(Q46605996)

English

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

scientific article published on 9 May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Klarissa Stürner

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Ivo Meinhold-Heerlein

5

object named as

Ivo Meinhold-Heerlein

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

8

object named as

Felix Hilpert

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

author name string

Christoph Mundhenke

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Marion Tina Weigel

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Frank Roesel

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Dirk O Bauerschlag

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Christian Schem

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Walter Jonat

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Nicolai Maass

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

publication date

9 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

134

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

1397-1405

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

https://scigraph.springernature.com/pub.10.1007/s00432-008-0408-0

0 references

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH- and NADPH-dependent dehydrogenase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Putting the rap on Akt.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2005

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor tyrosine kinase expression in human bone marrow stromal cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacology of imatinib (STI571).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human peripheral blood eosinophils express stem cell factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18465140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-008-0408-0

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18465140

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46605996&oldid=2121728406"